A robust animal model of state anxiety: Fear-potentiated behaviour in the elevated plus-maze

European Journal of Pharmacology

Volumn 463, Issue 1-3, 2003, Pages 163-175

  Korte, S Mechiel ^a   De Boer, Sietse F ^b  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Allostasis; Allostatic load; Allostatic state; Contextual conditioning; Controllability; Corticosteroid; Corticotropin releasing factor; Elevated plus maze; Enhanced anxiety state; Fear potentiation; Glucocorticoid receptor antagonist; State anxiety; Stress

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 AMINOBUTYRIC ACID RECEPTOR; 4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; BENZODIAZEPINE RECEPTOR; CORTICOTROPIN RELASING FACTOR[12-41][DEXTRO PHENYLALANINE]; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR[9-41]; DIAZEPAM; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; MESSENGER RNA; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; ORG 34580; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; UROCORTIN;

ANIMAL BEHAVIOR; ANIMAL HOUSING; ANXIETY DISORDER; AROUSAL; COGNITION; CONDITIONING; DOSE RESPONSE; DRUG EFFECT; EMOTION; EXPLORATORY BEHAVIOR; FEAR; HAZARD; MAZE TEST; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SHOCK; STRESS;

EID: 0037470187     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01279-2     Document Type: Review

References (127)

1. Adamec R.E., McKay D. Amygdala kindling, anxiety, and corticotrophin releasing factor (CRF). Physiol. Behav. 54:1993;423-431.
2. Adamec R.E., Shallow T. Lasting effects on rodent anxiety of a single exposure to a cat. Physiol. Behav. 54:1993;101-109.
3. Altemus M., Smith M.A., Diep V., Aulakh C.S., Murphy D.L. Increased mRNA for corticotrophin releasing hormone in the amygdala of fawn-hooded rats, a potential animal model of anxiety. Anxiety. 1:1994-1995;251-257.
4. Andersen I.L., Boe K.E., Foerevik G., Janczak A.M., Bakken M. Behavioural evaluation of methods for assessing fear responses in weaned pigs. Appl. Anim. Behav. Sci. 69:2000;227-240.
5. Arriza J.L., Simerly R.B., Swanson L.W., Evans R.M. The neuronal mineralocorticoid receptor as a mediator of glucocorticoid response. Neuron. 1:1988;887-900.
6. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., Britton K.T. CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology (Berl.). 103:1991;227-232.
7. Bohus B. Central nervous structures and the effect of ACTH and corticosteroids on avoidance behaviour, a study with intracerebral implantation of corticosteroids in the rat. Prog. Brain Res. 32:1970;171-184.
8. Bohus B. Limbic-midbrain mechanisms and behavioral physiology interactions with CRF, ACTH and adrenal hormones. Hellhammer D., Florin I., Weiner H. Neurobiological Approaches to Human Disease. 1987;267-285 Hans Huber Publishers, Toronto.
9. Bohus B., De Kloet E.R. Adrenal steroids and extinction behaviour, antagonism by progesterone, deoxycorticosterone and dexamethasone of a specific effect of corticosterone. Life Sci. 28:1981;433-440.
10. Bohus B., De Kloet E.R., Veldhuis H.D. Adrenal steroids and behavioral adaptation, relationship to brain corticoid receptors. Ganten D., Pfaff D. Adrenal Actions on Brain. 1982;107-148 Springer-Verlag, Berlin.
11. Buwalda B., de Boer S.F., Van Kalkeren A.A., Koolhaas J.M. Physiological and behavioral effects of chronic intracerebroventricular infusion of corticotropin-releasing factor in the rat. Psychoneuroendocrinology. 22:1997;297-309.
12. Caldji C., Tannenbaum B., Sharma S., Francis D., Plotsky P.M., Meaney M.J. Maternal care during infancy regulates the development of neural systems mediating the expression of fearfulness in the rat. Proc. Natl. Acad. Sci. 95:1998;5335-5340.
13. Calvo N., Volosin M. Glucocorticoid and mineralocorticoid receptors are involved in the facilitation of anxiety-like response induced by restraint. Neuroendocrinology. 73:2001;261-271.
14. Calvo N., Martijena I.D., Molina V.A., Volosin M. Metyrapone pretreatment prevents the behavioral and neurochemical sequelae induced by stress. Brain Res. 800:1998;227-235.
15. Cole B.J., Hillmann M., Seidelmann D., Klewer M., Jones G.H. Effects of benzodiazepine receptor partial inverse agonists in the elevated plus maze test of anxiety in the rat. Psychopharmacology (Berl.). 121:1995;118-126.
16. Contarino A., Dellu F., Koob G.F., Smith G.W., Lee K.F., Vale W., Gold L.H. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. 835:1999;1-9.
17. Cordero M.I., Sandi C. A role for brain glucocorticoid receptors in contextual fear-conditioning, dependence upon training intensity. Brain Res. 786:1998;11-17.
18. Cordero M.I., Merino J.J., Sandi C. Correlational relationship between shock intensity and corticosterone secretion on the establishment and subsequent expression of contextual fear-conditioning. Behav. Neurosci. 112:1998;885-891.
19. Coromidas K.P., LeDoux J.E., Gold P.W., Schulkin J. Corticosterone potentiation of conditioned fear in rats. Ann. N.Y. Acad. Sci. 746:1994;392-393.
20. Crabbe J.C., Wahlsten D., Dudek B.C. Genetics of mouse behavior, interactions with laboratory environment. Science. 284:1999;1670-1672.
21. Davis M. Are different parts of the extended amygdala involved in fear versus anxiety? Biol. Psychiatry. 44:1998;1239-1247.
22. De Kloet E.R. Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol. 12:1991;95-164.
23. De Kloet E.R., Rots N.Y., van den Berg D.T., Oitzl M.S. Brain mineralocorticoid receptor function. Ann. N.Y. Acad. Sci. 746:1994;20-21.
24. De Kloet E.R., Vreugdenhil E., Oitzl M.S., Joels M. Brain corticosteroid receptor balance in health and disease. Endocr. Rev. 19:1998;269-301.
25. De Kloet E.R., Oitzl M.S., Joels M. Stress and cognition, are corticosteroids good or bad guys? Trends Neurosci. 22:1999;422-426.
26. Falter U., Gower A.J., Gobert J. Resistance of baseline activity in the elevated plus-maze to exogenous influences. Behav. Pharmacol. 3:1992;123-128.
27. Fernandes C., File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol. Biochem. Behav. 54:1996;31-40.
28. Gold P.W., Goodwin F.K., Chrousos G.P. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress. N. Engl. J. Med. 319:1988;413-420.
29. Goldstein D.S., McEwen B. Allostasis, homeostats, and the nature of stress. Stress. 5:2002;55-58.
30. Grahn R.E., Kalman B.A., Brennan F.X., Watkins L.R., Maier S.F. The elevated plus-maze is not sensitive to the effect of stressor controllability in rats. Pharmacol. Biochem. Behav. 52:1995;565-570.
31. Greenwood-Van Meerveld B., Gibson M., Gunter W., Shepard J., Foreman R., Myers D. Stereotaxic delivery of corticosterone to the amygdala modulates colonic sensitivity in rats. Brain Res. 893:2001;135-142.
32. Heinrichs S.C., Pich E.M., Miczek K.A., Britton K.T., Koob G.F. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. 581:1992;190-197.
33. Heinrichs S.C., Menzaghi F., Pich E.M., Baldwin H.A., Rassnick S., Britton K.T., Koob G.F. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology. 11:1994;179-186.
34. Heinrichs S.C., Menzaghi F., Pich E.M., Britton K.T., Koob G.F. The role of CRF in behavioral aspects of stress. Ann. N.Y. Acad. Sci. 771:1995;92-104.
35. Heinrichs S.C., Lapsansky J., Lovenberg T.W., De Souza E.B., Chalmers T. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul. Pept. 71:1997;15-21.
36. Heinrichs S.C., Min H., Tamraz S., Carmouche M., Boehme S.A., Vale W.W. Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology. 22:1997;215-224.
37. Heinrichs S.C., De Souza E.B., Schulteis G., Lapsansky J.L., Grigoriadis D.E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology. 27:2002;194-202.
38. Herman J.P., Spencer R. Regulation of hippocampal glucocorticoid receptor gene transcription and protein expression in vivo. J. Neurosci. 18:1998;7462-7473.
39. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54:1996;21-30.
40. Holsboer F., Montkowski A. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul. Pept. 59:1995;229-239.
41. Honkaniemi J., Pelto-Huikko M., Rechardt L., Isola J., Lammi A., Fuxe K., Gustafsson J.A., Wikstrom A.C., Hokfelt T. Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. Neuroendocrinology. 55:1992;451-459.
42. Hsu S.Y., Hsueh A.J. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat. Med. 7:2001;605-611.
43. Hsu D.T., Chen F.L., Takahashi L.K., Kalin N.H. Rapid stress-induced elevations in corticotropin-releasing hormone mRNA in rat central amygdala nucleus and hypothalamic paraventricular nucleus, an in situ hybridization analysis. Brain Res. 788:1998;305-310.
44. Imaki T., Nahan J.L., Rivier C., Sawchenko P.E., Vale W. Differential regulation of corticotropin-releasing factor mRNA in rat brain regions by glucocorticoids and stress. J. Neurosci. 11:1991;585-599.
45. Kabbaj M., Devine D.P., Savage V.R., Akil H.J. Neurobiological correlates of individual differences in novelty-seeking behavior in the rat, differential expression of stress-related molecules. Neuroscience. 20:2000;6983-6988.
46. Kalin N.H., Takahashi L.K., Chen F.L. Restraint stress increases corticotropin-releasing hormone mRNA content in the amygdala and paraventricular nucleus. Brain Res. 656:1994;182-186.
47. Koob G.F. Corticotropin-releasing factor, norepinephrine, and stress. Biol. Psychiatry. 46:1999;1167-1180.
48. Koob G.F., Heinrichs S.C. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res. 848:1999;141-145.
49. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 24:2001;97-129.
50. Koob G.F., Heinrichs S.C., Pich E.M., Menzaghi F., Baldwin H., Miczek K., Britton K.T. The role of corticotropin-releasing factor in behavioural responses to stress. Ciba Found. Symp. 172:1993;277-289.
51. Koolhaas J.M., De Boer S.F., De Ruiter A.J., Meerlo P., Sgoifo A. Social stress in rats and mice. Acta Physiol. Scand. 640:1997;69-72. (Suppl.).
52. Koolhaas J.M., Korte S.M., De Boer S.F., Van Der Vegt B.J., Van Reenen C.G., Hopster H., De Jong I.C., Ruis M.A., Blokhuis H.J. Coping styles in animals, current status in behavior and stress-physiology. Neurosci. Biobehav. Rev. 23:1999;925-935.
53. Korte S.M. Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci. Biobehav. Rev. 25:2001;117-142.
54. Korte S.M., Buwalda B., Bouws G.A., Koolhaas J.M., Maes F.W., Bohus B. Conditioned neuroendocrine and cardiovascular stress responsiveness accompanying behavioral passivity and activity in aged and in young rats. Physiol. Behav. 51:1992;815-822.
55. Korte S.M., Eisinga W., Timmerman W., Nyakas C., Bohus B. Behavioral and cardiac responses after intracerebroventricular corticotropin-releasing hormone (CRH) administration, role of adrenal cortical hormones. Horm. Behav. 26:1992;375-384.
56. Korte S.M., Bouws G.A., Bohus B. Adrenal hormones in rats before and after stress-experience: effects of ipsapirone. Physiol. Behav. 51:1992;1129-1133.
57. Korte S.M., de Boer S.F., de Kloet E.R., Bohus B. Anxiolytic-like effects of selective mineralocorticoid and glucocorticoid antagonists on fear-enhanced behavior in the elevated plus-maze. Psychoneuroendocrinology. 20:1995;385-394.
58. Korte S.M., De Kloet E.R., Buwalda B., Bouman S.D., Bohus B. Antisense to the glucocorticoid receptor in hippocampal dentate gyrus reduces immobility in forced swim test. Eur. J. Pharmacol. 301:1996;19-25.
59. Korte S.M., De Boer S.F., Bohus B. Fear-potentiation in the elevated plus-maze test depends on stressor controllability and fear conditioning. Stress. 3:1999;27-40.
60. Lechner S.M., Valentino R.J. Glucocorticoid receptor-immunoreactivity in corticotrophin-releasing factor afferents to the locus coeruleus. Brain Res. 816:1999;17-28.
61. LeDoux J.E. Emotional memory systems in the brain. Behav. Brain Res. 58:1993;69-79.
62. LeDoux J.E. Emotion, clues from the brain. Annu. Rev. Psychol. 46:1995;209-235.
63. Lee Y., Davis M. Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing hormone on the acoustic startle reflex. J. Neurosci. 17:1997;6434-6446.
64. Lee Y., Schulkin J., Davis M. Effect of corticosterone on the enhancement of the acoustic startle reflex by corticotropin releasing factor (CRF). Brain Res. 12:1994;93-98.
65. Li C., Vaughan J., Sawchenko P.E., Vale W.W. Urocortin III-immunoreactive projections in rat brain, partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J. Neurosci. 1:2002;991-1001.
66. Liebsch G., Landgraf R., Gerstberger R., Probst J.C., Wotjak C.T., Engelmann M., Holsboer F., Montkowski A. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul. Pept. 59:1995;229-239.
67. Liebsch G., Landgraf R., Engelmann M., Lorscher P., Holsboer F. Differential behavioural effects of chronic infusion of CRH1 and CRH2 receptor antisense oligonucleotides into the rat brain. J. Psychiatr. Res. 33:1999;153-163.
68. Lopez J.F., Chalmers D.T., Little K.Y., Watson S.J. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus, implications for the neurobiology of depression. Biol. Psychiatry. 43:1998;547-573.
69. Maisonnette S., Morato S., Brandao M.L. Role of resocialization and of 5-HT1A receptor activation on the anxiogenic effects induced by isolation in the elevated plus-maze test. Physiol. Behav. 54:1993;753-758.
70. Makino S., Gold P.W., Schulkin J. Corticosterone effects on corticotropin-releasing hormone mRNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus. Brain Res. 640:1994;105-112.
71. Makino S., Gold P.W., Schulkin J. Effects of corticosterone on CRH mRNA and content in the bed nucleus of the stria terminalis, comparison with the effects in the central nucleus of the amygdala and the paraventricular nucleus of the hypothalamus. Brain Res. 657:1994;141-149.
72. Makino S., Schulkin J., Smith M.A., Pacak K., Palkovits M., Gold P.W. Regulation of corticotropin-releasing hormone receptor messenger ribonucleic acid in the rat brain and pituitary by glucocorticoids and stress. Endocrinology. 136:1995;4517-4525.
73. Makino S., Hashimoto K., Gold P.W. Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress. Pharmacol. Biochem. Behav. 73:2002;147-158.
74. Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.F. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 20:1998;1093-1102.
75. Martijena I.D., Calvo N., Volosin M., Molina V.A. Prior exposure to a brief restraint session facilitates the occurrence of fear in response to a conflict situation: behavioral and neurochemical correlates. Brain Res. 752:1997;136-142.
76. McEwen B.S. Endocrine effects on the brain and their relationship to behavior. Siegel S.J. Basic Neurochemistry, Molecular, Cellular, and Medical Aspects. 1993;1003-1023 Raven Press, New York.
77. McEwen B.S. Stress, adaptation, and disease. Allostasis and allostatic load. Ann. N.Y. Acad. Sci. 840:1998;33-44.
78. McEwen B.S. Allostasis and allostatic load, implications for neuropsychopharmacology. Neuropsychopharmacology. 22:2000;108-124.
79. McEwen B.S., Stellar E. Stress and the individual. Mechanisms leading to disease. Arch. Intern. Med. 153:1993;2093-2101.
80. Mendonca F.H., Guimaraes F.S. Intra-hippocampal administration of cycloheximide attenuates the restraint-induced exploratory deficit of an elevated plus maze. Behav. Brain Res. 91:1998;207-211.
81. Menzaghi F., Howard R.L., Heinrichs S.C., Vale W., Rivier J., Koob G.F. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J. Pharmacol. Exp. Ther. 269:1994;564-572.
82. Moreau J.L., Kilpatrick G., Jenck F. Urocortin, a novel neuropeptide with anxiogenic-like properties. NeuroReport. 8:1997;1697-1701.
83. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., Vale W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 226:1984;1342-1344.
84. Palkovits M., Young W.S. III, Kovacs K., Toth Z.S., Makara G.B. Alterations in corticotropin-releasing hormone gene expression of central amygdaloid neurons following long-term paraventricular lesions and adrenalectomy. Neuroscience. 85:1998;1351-1447.
85. Pellow S., Chopin P., File S.E., Briley M. Validation of open, closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
86. Pich E.M., Lorang M., Yeganeh M., Rodriguez de Fonseca F., Raber J., Koob G.F., Weiss F. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J. Neurosci. 15:1995;5439-5447.
87. Potter E., Sutton S., Donaldson C., Chen R., Perrin M., Lewis K., Sawchenko P.E., Vale W. Distribution of corticotropin-releasing factor receptor mRNA expression in therat brain and pituitary. Proc. Natl. Acad. Sci. 91:1994;8777-8781.
88. Quirarte G.L., Galvez R., Roozendaal B., McGaugh J.L. Norepinephrine release in the amygdala in response to footshock and opioid peptidergic drugs. Brain Res. 808:1998;134-140.
89. Raber J., Koob G.F., Bloom F.E. Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling, comparison with the hypothalamic response. J. Pharmacol. Exp. Ther. 272:1995;815-824.
90. Radulovic J., Ruhmann A., Liepold T., Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress, differential roles of CRF receptors 1 and 2. J. Neurosci. 19:1999;5016-5025.
91. Ratka A., Sutanto W., Bloemers M., De Kloet E.R. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology. 50:1989;117-123.
92. Reul J.M.H.M., De Kloet E.R. Two receptor systems for corticosterone in rat brain, microdistribution and differential occupation. Endocrinology. 117:1985;2505-2511.
93. Reul J.M., Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2:2002;23-33.
94. Rivier J., Vale W., Koob F. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology (Berl.). 160:2002;113-121.
95. Rodgers R.J., Cole J.C. Anxiety enhancement in the murine elevated plus maze by immediate prior exposure to social stressors. Physiol. Behav. 53:1993;383-388.
96. Rodgers R.J., Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci. Biobehav. Rev. 21:1997;801-810.
97. Roozendaal B. 1999 Curt P. Richter Award. Glucocorticoids and the regulation of memory consolidation. Psychoneuroendocrinology. 25:2000;213-238.
98. Roozendaal B., Koolhaas J.M., Bohus B. Attenuated cardiovascular, neuroendocrine, and behavioral responses after a single footshock in central amygdaloid lesioned male rats. Physiol. Behav. 50:1991;771-775.
99. Roozendaal B., Bohus B., McGaugh J.L. Dose-dependent suppression of adrenocortical activity with metyrapone, effects on emotion and memory. Psychoneuroendocrinology. 21:1996;681-693.
100. Ruis M.A., te Brake J.H., Buwalda B., De Boer S.F., Meerlo P., Korte S.M., Blokhuis H.J., Koolhaas J.M. Housing familiar male wildtype rats together reduces the long-term adverse behavioural and physiological effects of social defeat. Psychoneuroendocrinology. 24:1999;285-300.
101. Sandi C. The role and mechanisms of action of glucocorticoid involvement in memory storage. Neural Plast. 6:1998;41-52.
102. Sapolsky R.M., Romero L.M., Munck A.U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21:2000;55-89.
103. Schulkin J. Corticotropin-releasing hormone signals adversity in both the placenta and the brain, regulation by glucocorticoids and allostatic overload. J. Endocrinol. 161:1999;349-356.
104. Schulkin J., McEwen B.S., Gold P.W. Allostasis, amygdala, and anticipatory angst. Neurosci. Biobehav. Rev. 18:1994;385-396.
105. Schulkin J., Gold P.W., McEwen B.S. Induction of corticotropin-releasing hormone gene expression by glucocorticoids, implication for understanding the states of fear and anxiety and allostaticload. Psychoneuroendocrinology. 23:1998;219-243.
106. Shepard J.D., Barron K.W., Myers D.A. Corticosterone delivery to the amygdala increases corticotropin-releasing factor mRNA in the central amygdaloid nucleus and anxiety-like behavior. Brain Res. 861:2000;288-295.
107. Skutella T., Probst J.C., Renner U., Holsboer F., Behl C. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience. 85:1998;795-805.
108. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.F. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 20:1998;1093-1102.
109. Spencer R.L., Miller A.H., Stein M., McEwen B.S. Corticosterone regulation of type I and type II adrenal steroid receptors in brain, pituitary, and immune tissue. Brain Res. 549:1991;236-246.
110. Spina G., Merlo-Pich E., Akwa Y., Balducci C., Basso M., Zorrilla P., Britton T., Rivier J., Vale W., Koob G.F. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology (Berl.). 160:2002;113-121.
111. Steenbergen H.L., Farabollini F., Heinsbroek R.P., Van de Poll N.E. Sex-dependent effects of aversive stimulation on holeboard and elevated plus-maze behavior. Behav. Brain Res. 43:1991;159-165.
112. Stenzel-Poore M.P., Heinrichs S.C., Rivest S., Koob G.F., Vale W.W. Overproduction of corticotropin-releasing factor in transgenic mice, a genetic model of anxiogenic behavior. J. Neurosci. 14:1994;2579-2584.
113. Sterling P., Eyer J. Allostasis, a new paradigm to explain arousal pathology. Fisher S., Reason J. Handbook of Life Stress, Cognition and Health. 1988;629-649 Wiley, Chichester.
114. Swanson L.W., Simmons D.M. Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus, a hybridization histochemical study in the rat. J. Comp. Neurol. 285:1989;413-435.
115. Takahashi L.K., Ho S.P., Livanov V., Graciani N., Arneric S.P. Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. Brain Res. 902:2001;135-142.
116. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44:1993;463-469.
117. Valdez G.R., Inoue K., Koob G.F., Rivier J., Vale W., Zorrilla E.P. Human urocortin II, mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res. 943:2002;142-150.
118. Van Bockstaele E.J., Colago E.E., Valentino R.J. Amygdaloid corticotropin-releasing factor targets locus coeruleus dendrites, substrate for the co-ordination of emotional and cognitive limbs of the stress response. J. Neuroendocrinol. 10:1998;743-757.
119. Van Bockstaele E.J., Peoples J., Valentino R.J. A.E. Bennett Research Award. Anatomic basis for differential regulation of the rostrolateral peri-locus coeruleus region by limbic afferents. Biol. Psychiatry. 46:1999;1352-1363.
120. Van Bockstaele E.J., Bajic D., Proudfit H., Valentino R.J. Topographic architecture of stress-related pathways targeting the noradrenergic locus coeruleus. Physiol. Behav. 73:2001;273-283.
121. Watts A.G., Sanchez-Watts G. Region-specific regulation of neuropeptide mRNAs in rat limbic forebrain neurones by aldosterone and corticosterone. J. Physiol. 484:1995;721-736.
122. Weiss J.M. Effects of coping responses on stress. J. Comp. Physiol. Psychol. 65:1968;251-260.
123. Weninger S.C., Dunn A.J., Muglia L.J., Dikkes P., Miczek K.A., Swiergiel A.H., Berridge C.W., Majzoub J.A. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc. Natl. Acad. Sci. 96:1999;8283-8288.
124. Wong M.L., Kling M.A., Munson P.J., Listwak S., Licinio J., Prolo P., Karp B., McCutcheon I.E., Geracioti T.D. Jr., DeBellis M.D., Rice K.C., Goldstein D.S., Veldhuis J.D., Chrousos G.P., Oldfield E.H., McCann S.M., Gold P.W. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features, relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl. Acad. Sci. 97:2000;325-330.
125. Wotjak C.T., Kubota M., Liebsch G., Montkowski A., Holsboer F., Neumann I., Landgraf R. Release of vasopressin within the rat paraventricular nucleus in response to emotional stress, a novel mechanism of regulating adrenocorticotropic hormone secretion? J. Neurosci. 16:1996;7725-7732.
126. Yehudam R., Southwick S.M., Krystal J.H., Bremner D., Charney D.S., Mason J.W. Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am. J. Psychiatry. 150:1993;83-86.
127. Zangrossi H. Jr., File S.E. Behavioral consequences in animal tests of anxiety and exploration of exposure to cat odor. Brain. Res. Bull. 29:1992;381-388.